EcoDrugPlus

Activin Receptor Type-2b-Like

Ensembl ID : ENSOTSG00005032004
Gene Symbol: LOC112215332
3 Cross references
187 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSOTSG00005035029
Gene Symbol: ADORA1
3 Cross references
187 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSOTSG00005005002
Gene Symbol: ADORA1
1 Cross references
198 Possible Orthologues:

Adenosine A1 Receptor B

Ensembl ID : ENSOTSG00005007899
Gene Symbol: ADORA1B
1 Cross references
149 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSOTSG00005039855
Gene Symbol: ADORA2A
1 Cross references
190 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSOTSG00005035969
Gene Symbol: ADORA2A
1 Cross references
192 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSOTSG00005043587
Gene Symbol: ADORA2A
1 Cross references
192 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSOTSG00005026974
Gene Symbol: ADORA2B
1 Cross references
191 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSOTSG00005035162
Gene Symbol: ADORA2B
1 Cross references
192 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSOTSG00005029644
Gene Symbol: ADORA3
3 Cross references
134 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSOTSG00005000911
Gene Symbol: ADORA3
3 Cross references
133 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSOTSG00005042885
Gene Symbol: ADA
1 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).